A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: Analysis of 14,678 patients using systematic review and meta-analytical tools

Journal of Clinical Neuroscience

Volumn 22, Issue 5, 2015, Pages 785-799

  Thuy, Matthew N T ^a   Kam, Jeremy K T ^a   Lee, Geoffrey C Y ^a   Tao, Peter L ^a   Ling, Dorothy Q ^a   Cheng, Melissa ^a   Goh, Su Kah ^a   Papachristos, Alexander J ^a   Shukla, Lipi ^a   Wall, Krystal Leigh ^a   Smoll, Nicolas R ^a   Jones, Jordan J ^a   Gikenye, Njeri ^a   Soh, Bob ^a   Moffat, Brad ^a   Johnson, Nick ^a   Drummond, Katharine J ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Adults; Glioblastoma; Meta analysis; Neurosurgery; Survival; Systematic review

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE; CATHEPSIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; FASCIN; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; NESTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; GENETIC MARKER;

CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 10; CHROMOSOME 10Q; CHROMOSOME 17; CHROMOSOME 19; CHROMOSOME 20P; CHROMOSOME 20Q; CHROMOSOME LOSS; GENE; GENE MUTATION; GLIOBLASTOMA; HUMAN; IDH1 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SURVIVAL PREDICTION; SURVIVAL RATE; SYSTEMATIC REVIEW; ADULT; BRAIN NEOPLASMS; FEMALE; GENETIC MARKER; GENETICS; MALE; META ANALYSIS; MIDDLE AGED; MORTALITY; MUTATION; PREDICTIVE VALUE; PROGNOSIS; TRENDS;

ADULT; BIOMARKERS; BRAIN NEOPLASMS; FEMALE; GENETIC MARKERS; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE;

EID: 84927178674     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2014.10.029     Document Type: Review

References (312)

1. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma Engl J Med 352 2005 987 996
2. M.E. Hegi, A.C. Diserens, and S. Godard Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res 10 2004 1871 1874
3. J. Dunn, A. Baborie, and F. Alam Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy Br J Cancer 101 2009 124 131
4. C.K. Park, S.H. Park, and S.H. Lee Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin Neuropathology 29 2009 443 449
5. M. Preusser, R. Charles Janzer, and J. Felsberg Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker Brain Pathol 18 2008 520 532
6. M. Wager, P. Menei, and J. Guilhot Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study Br J Cancer 98 2008 1830 1838
7. D.W. Parsons, S. Jones, and X. Zhang An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
8. M. Sanson, Y. Marie, and S. Paris Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas J Clin Oncol 27 2009 4150 4154
9. Y. Sonoda, T. Kumabe, and T. Nakamura Analysis of IDH1 and IDH2 mutations in Japanese glioma patients Cancer Sci 100 2009 1996 1998
10. M. Weller, J. Felsberg, and C. Hartmann Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German glioma network J Clin Oncol 27 2009 5743 5750
11. H. Yan, D.W. Parsons, and G. Jin IDH1 and IDH2 mutations in gliomas N Engl J Med 360 2009 765 773
12. M.K. Parmar, V. Torri, and L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834
13. R Development Core Team R: A language and environment for statistical computing 2008 R Foundation for Statistical Computing Vienna, Austria ISBN 3-900051-07-0, URL: http://www.R-project.org
14. Lumley T. Rmeta version 2.10. R package; 2003.
15. C. Aaberg-Jessen, K. Christensen, and H. Offenberg Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival J Neurooncol 95 2009 117 128
16. M. Abou-Ghazal, D.S. Yang, and W. Qiao The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas Clin Cancer Res 14 2008 8228 8235
17. K.D. Aldape, K. Ballman, and A. Furth Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance J Neuropathol Exp Neurol 63 2004 700 707
18. M.-C. Amoureux, B. Coulibaly, and O. Chinot Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines BMC Cancer 10 2010 91
19. T. Anda, H.K. Shabani, and K. Tsunoda Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis Neurol Res 25 2003 241 248
20. U. Andersson, P. Osterman, and S. Sjostrom MNS16A minisatellite genotypes in relation to risk of glioma and meningioma and to glioblastoma outcome Int J Cancer 125 2009 968 972
21. H. Aoki, Y. Kondo, and K. Aldape Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3 Autophagy 4 2008 467 475
22. H. Aoki, T. Yokoyama, and K. Fujiwara Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma Clin Cancer Res 13 2007 6603 6609
23. L.M. Backlund, B.R. Nilsson, and H.M. Goike Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN Clin Cancer Res 9 2003 4151 4158
24. S. Balesaria, C. Brock, and M. Bower Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas Br J Cancer 81 1999 1371 1377
25. K.C. Barbosa, S.M. Oba-Shinjo, and M. Uno Association of EGFR c.2073A>T polymorphism with decreased risk of diffusely infiltrating astrocytoma in a Brazilian case-control study. Int J Biol 23 2008 140 146
26. J.A. Barnett, D.L. Urbauer, and G.I. Murray Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target Clin Cancer Res 13 2007 3559 3567
27. T.T. Batchelor, R.A. Betensky, and J.M. Esposito Age-dependent prognostic effects of genetic alterations in glioblastoma Clin Cancer Res 10 2004 228 233
28. P. Birner, M. Piribauer, and I. Fischer Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes Brain Pathol 13 2003 133 143
29. P. Birner, M. Piribauer, and I. Fischer Prognostic relevance of p53 protein expression in glioblastoma Oncol Rep 9 2002 703 707
30. J.L. Blanc, M. Wager, and J. Guilhot Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas J Neurooncol 68 2004 275 283
31. F.E. Bleeker, N.A. Atai, and S. Lamba The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma Acta Neuropathol 119 2010 487 494
32. B. Boisselier, Y. Marie, and S. El Hallani No association of (-131C→G) variant of CHI3L1 gene with risk of glioblastoma and prognosis J Neurooncol 94 2009 169 172
33. J.L. Boulay, A.R. Miserez, and C. Zweifel Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors PLoS ONE 2 2007 e576
34. C. Bouvier-Labit, O. Chinot, and C. Ochi Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas Neuropathol Appl Neurobiol 24 1998 381 388
35. A.A. Brandes, E. Franceschi, and A. Tosoni O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications Neuro Oncol 12 2010 283 288
36. A.A. Brandes, E. Franceschi, and A. Tosoni MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2008 2192 2197
37. M. Bredel, C. Bredel, and D. Juric Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas J Clin Oncol 24 2006 274 287
38. M. Bredel, M. Piribauer, and C. Marosi High expression of DNA topoisomerase II alpha and Ki-67 antigen is associated with prolonged survival in glioblastoma patients Eur J Cancer 38 2002 1343 1347
39. M. Bredel, D.M. Scholtens, and G.R. Harsh A network model of a cooperative genetic landscape in brain tumors JAMA 302 2009 261 275
40. R. Britto, S. Umesh, and A.S. Hegde Shift in AP-2alpha localization characterizes astrocytoma progression Cancer Biol Ther 6 2007 413 418
41. A.M. Buccoliero, A. Caldarella, and C.F. Gheri Inducible cyclooxygenase (COX-2) in glioblastoma-clinical and immunohistochemical (COX-2-VEGF) correlations Clin Neuropathol 25 2006 59 66
42. E.C. Burton, K.R. Lamborn, and B.G. Feuerstein Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma Cancer Res 62 2002 6205 6210
43. E.C. Burton, K.R. Lamborn, and P. Forsyth Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors Clin Cancer Res 8 2002 180 187
44. V.T. Cao, T.Y. Jung, and S. Jung The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas Neurosurgery 65 2009 866 875 [discussion 875]
45. D. Capper, M. Mittelbronn, and R. Meyermann Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach Acta Neuropathol 115 2008 249 259
46. M.R. Carlson, W.B. Pope, and S. Horvath Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2 Clin Cancer Res 13 2007 2592 2598
47. C. Carpentier, F. Laigle-Donadey, and Y. Marie Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma Neurology 67 2006 872 874
48. C. Carpentier, J. Lejeune, and F. Gros Association of telomerase gene hTERT polymorphism and malignant gliomas J Neurooncol 84 2007 249 253
49. P.F. Cartron, L. Oliver, and S. Martin The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, is correlated with an increased survival of glioblastoma multiforme patients Hum Mol Genet 11 2002 675 687
50. A. Chakravarti, M.A. Delaney, and E. Noll Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas Clin Cancer Res 7 2001 2387 2395
51. A. Chakravarti, E. Noll, and P.M. Black Quantitatively determined survivin expression levels are of prognostic value in human gliomas J Clin Oncol 20 2002 1063 1068
52. A. Chakravarti, W. Seiferheld, and X. Tu Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 62 2005 318 327
53. A. Chakravarti, G. Zhai, and Y. Suzuki The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas J Clin Oncol 22 2004 1926 1933
54. Y.J. Chen, V. Hakin-Smith, and M. Teo Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma Cancer Res 66 2006 6473 6476
55. Z.P. Chen, D. Yarosh, and Y. Garcia Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients Can J Neurol Sci 26 1999 104 109
56. P. Chinnaiyan, M. Wang, and A.M. Rojiani The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group Radiat Oncol 3 2008 32
57. O.L. Chinot, M. Barrie, and S. Fuentes Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide J Clin Oncol 25 2007 1470 1475
58. G. Choe, J.K. Park, and L. Jouben-Steele Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype Clin Cancer Res 8 2002 2894 2901
59. K. Christensen, H.D. Schroder, and B.W. Kristensen CD133 identifies perivascular niches in grade II-IV astrocytomas J Neurooncol 90 2008 157 170
60. H. Colman, L. Zhang, and E.P. Sulman A multigene predictor of outcome in glioblastoma Neuro Oncol 12 2009 49 57
61. B.M. Costa, P. Ferreira, and S. Costa Association between functional EGF+61 polymorphism and glioma risk Clin Cancer Res 13 2007 2621 2626
62. B.M. Costa, J.S. Smith, and Y. Chen Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma Cancer Res 70 2010 453 462
63. B. Coulibaly, I. Nanni, and B. Quilichini Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression Hum Pathol 41 2010 815 823
64. E. Criniere, G. Kaloshi, and F. Laigle-Donadey MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities J Neurooncol 83 2007 173 179
65. E. Cuny, H. Loiseau, and G. Penchet Association of elevated glial expression of interleukin-1beta with improved survival in patients with glioblastomas multiforme J Neurosurg 96 2002 294 301
66. M. Dimitriadi, G. Poulogiannis, and L. Liu P53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours Br J Cancer 99 2008 1144 1152
67. V. Donato, A. Papaleo, and A. Castrichino Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide Tumori 93 2007 248 256
68. S. El Hallani, F. Ducray, and A. Idbaih TP53 codon 72 polymorphism is associated with age at onset of glioblastoma Neurology 72 2009 332 336
69. S. El Hallani, Y. Marie, and A. Idbaih No association of MDM2 SNP309 with risk of glioblastoma and prognosis J Neurooncol 85 2007 241 244
70. M. Eoli, F. Menghi, and M.G. Bruzzone Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival Clin Cancer Res 13 2007 2606 2613
71. R.P. Ermoian, C.S. Furniss, and K.R. Lamborn Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival Clin Cancer Res 8 2002 1100 1106
72. A. Ernst, S. Hofmann, and R. Ahmadi Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival Clin Cancer Res 15 2009 6541 6550
73. C. Fels, C. Schafer, and B. Huppe Bcl-2 expression in higher-grade human glioma: a clinical and experimental study J Neurooncol 48 2000 207 216
74. T. Flannery, S. McQuaid, and C. McGoohan Cathepsin S expression: an independent prognostic factor in glioblastoma tumours-A pilot study Int J Cancer 119 2006 854 860
75. S.P. Fortin, M.J. Ennis, and B.A. Savitch Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function Mol Cancer Res 7 2009 1871 1881
76. B. Frankel, S.L. Longo, and C. Leach Apoptosis and survival in high-grade astrocytomas as related to tumor Fas (APO-1/CD95) expression J Neurooncol 59 2002 27 34
77. T. Fukushima, A. Favereaux, and H. Huang Genetic alterations in primary glioblastomas in Japan J Neuropathol Exp Neurol 65 2006 12 18
78. T. Fukushima, Y. Katayama, and T. Watanabe Promoter hypermethylation of mismatch repair gene hMLH1 predicts the clinical response of malignant astrocytomas to nitrosourea Clin Cancer Res 11 2005 1539 1544
79. C.E. Furneaux, E.S. Marshall, and K. Yeoh Cell cycle times of short-term cultures of brain cancers as predictors of survival Br J Cancer 99 2008 1678 1683
80. M. Gadji, D. Fortin, and A.-M. Tsanaclis Three-dimensional nuclear telomere architecture is associated with differential time to progression and overall survival in glioblastoma patients Neoplasia 12 2010 183 191
81. P. Gaetani, E. Hulleman, and D. Levi Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study Tumori 96 2010 97 102
82. E. Galanis, J. Buckner, and D. Kimmel Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas Int J Oncol 13 1998 717 724
83. N. Genkai, J. Homma, and M. Sano Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients Oncol Rep 15 2006 1569 1574
84. E.R. Gerstner, S. Yip, and D.L. Wang Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma Neurology 73 2009 1509 1510
85. J. Godlewski, M.O. Nowicki, and A. Bronisz MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells Mol Cell 37 2010 620 632
86. T. Gorlia, M.J. van den Bent, and M.E. Hegi Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 Lancet Oncol 9 2008 29 38
87. L.A.M. Gravendeel, M.C.M. Kouwenhoven, and O. Gevaert Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology Cancer Res 69 2009 9065 9072
88. J.M. Grunda, L.B. Nabors, and C.A. Palmer Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM) J Neurooncol 80 2006 261 274
89. M.L. Grunnet, A. O'Neill, and M. Gilbert Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with an ECOG protocol of pre-irradiation chemotherapy Clin Neuropathol 19 2000 230 234
90. A. Gunal, O. Onguru, and M. Safali Fascin expression [corrected] in glial tumors and its prognostic significance in glioblastomas Neuropathology 28 2008 382 386
91. J. Haapasalo, K. Nordfors, and S. Jarvela Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy Neuro Oncol 9 2007 308 313
92. J.A. Haapasalo, K.M. Nordfors, and M. Hilvo Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis Clin Cancer Res 12 2006 473 477
93. C. Haberler, E. Gelpi, and C. Marosi Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy J Neurooncol 76 2006 105 109
94. V. Hakin-Smith, D.A. Jellinek, and D. Levy Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme Lancet 361 2003 836 838
95. M.A. Heesters, J. Koudstaal, and K.G. Go Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value J Neurooncol 44 1999 255 266
96. M.E. Hegi MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 10
97. A.B. Heimberger, M. Abou-Ghazal, and C. Reina-Ortiz Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas Clin Cancer Res 14 2008 5166 5172
98. A.B. Heimberger, R. Hlatky, and D. Suki Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients Clin Cancer Res 11 2005 1462 1466
99. J.W. Herms, F.D. von Loewenich, and J. Behnke C-myc oncogene family expression in glioblastoma and survival Surg Neurol 51 1999 536 542
100. E. Hervouet, E. Debien, and L. Campion Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation Clin Cancer Res 15 2009 3519 3529
101. C. Hill, S.B. Hunter, and D.J. Brat Genetic markers in glioblastoma: prognostic significance and future therapeutic implications Adv Anat Pathol 10 2003 212 217
102. D.A. Hilton, M. Penney, and L. Pobereskin Histological indicators of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival Histopathology 44 2004 555 560
103. S. Hiraga, T. Ohnishi, and S. Izumoto Telomerase activity and alterations in telomere length in human brain tumors Cancer Res 58 1998 2117 2125
104. T. Hiura, H. Khalid, and H. Yamashita Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival Cancer 83 1998 2361 2369
105. D.M.T. Ho, C.Y. Hsu, and L.T. Ting MIB-1 and DNA topoisomerase II alpha could be helpful for predicting long-term survival of patients with glioblastoma Am J Clin Pathol 119 2003 715 722
106. T. Homma, T. Fukushima, and S. Vaccarella Correlation among pathology, genotype, and patient outcomes in glioblastoma J Neuropathol Exp Neurol 65 2006 846 854
107. H. Horiguchi, T. Hirose, and T. Sano Loss of chromosome 10 in glioblastoma: relation to proliferation and angiogenesis Pathol Int 49 1999 681 686
108. S. Horvath, B. Zhang, and M. Carlson Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target Proc Natl Acad Sci U S A 103 2006 17402 17407
109. C. Houillier, J. Lejeune, and A. Benouaich-Amiel Prognostic impact of molecular markers in a series of 220 primary glioblastomas Cancer 106 2006 2218 2223
110. E. Hulleman, M. Quarto, and R. Vernell A role for the transcription factor HEY1 in glioblastoma J Cell Mol Med 13 2009 136 146
111. K.S. Hung, and S.L. Howng Prognostic significance of annexin VII expression in glioblastomas multiforme in humans J Neurosurg 99 2003 886 892
112. M. Hutterer, P. Knyazev, and A. Abate Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme Clin Cancer Res 14 2008 130 138
113. S.L. Hwang, Y.R. Hong, and C.Y. Chai Prognostic evaluation in supratentorial astrocytic tumors using p53, epidermal growth factor receptor, c-erbB-2 immunostaining Kaohsiung J Med Sci 14 1998 607 615
114. S.L. Hwang, Y.R. Hong, and A.S. Lieu Clinical significance of distribution patterns of P53 immunoreactivity in astrocytic tumors Kaohsiung J Med Sci 16 2000 279 284
115. K. Ichimura, A.P. Vogazianou, and L. Liu 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas Oncogene 27 2008 2097 2108
116. A. Idbaih, J. Aimard, and B. Boisselier Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma Neuropathol Appl Neurobiol 35 2009 208 213
117. N. Irie, T. Matsuo, and I. Nagata Protocol of radiotherapy for glioblastoma according to the expression of HIF-1 Brain Tumor Pathol 21 2004 1 6
118. J. Jaalinoja, R. Herva, and M. Korpela Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms J Neurooncol 46 2000 81 90
119. C.D. James, E. Galanis, and L. Frederick Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation Int J Oncol 15 1999 547 553
120. S. Jarvela, S. Jarvella, and H. Helin Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival Neuropathol Appl Neurobiol 32 2006 441 450
121. S. Jarvela, I. Rantala, and A. Rodriguez Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors BMC Cancer 10 2010 104
122. E. Jesien-Lewandowicz, D. Jesionek-Kupnicka, and I. Zawlik High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations Cancer Genet Cytogenet 188 2009 77 82
123. G. Kaloshi, K. Mokhtari, and C. Carpentier FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status J Neurooncol 84 2007 245 248
124. 6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy Neurosurgery 54 2004 349 357 [discussion 357]
125. T. Kamiryo, K. Tada, and S. Shiraishi Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme J Neurosurg 96 2002 815 822
126. D. Kaneshiro, T. Kobayashi, and S.T. Chao Chromosome 1p and 19q deletions in glioblastoma multiforme Appl Immunohistochem Mol Morphol 17 2009 512 516
127. M. Kappadakunnel, A. Eskin, and J. Dong Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone J Neurooncol 96 2009 359 367
128. S. Karcher, H.-H. Steiner, and R. Ahmadi Different angiogenic phenotypes in primary and secondary glioblastomas Int J Cancer 118 2006 2182 2189
129. H. Kato, M. Fujimura, and T. Kumabe PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma J Clin Neurosci 11 2004 37 41
130. R.G. Khatri, K. Navaratne, and R.J. Weil The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme J Neurosurg 109 2008 842 848
131. H. Kim, W. Huang, and X. Jiang Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship Proc Natl Acad Sci U S A 107 2010 2183 2188
132. L.J. Kirkegaard, P.B. DeRose, and B. Yao Image cytometric measurement of nuclear proliferation markers (MIB-1, PCNA) in astrocytomas Prognostic significance Am J Clin Pathol 109 1998 69 74
133. B.K. Kleinschmidt-DeMasters, K.O. Lillehei, and M. Varella-Garcia Glioblastomas in the older old Arch Pathol Lab Med 129 2005 624 631
134. B.K. Kleinschmidt-DeMasters, L. Meltesen, and L. McGavran Characterization of glioblastomas in young adults Brain Pathol 16 2006 273 286
135. T. Kobayashi, J. Masumoto, and T. Tada Prognostic significance of the immunohistochemical staining of cleaved caspase-3, an activated form of caspase-3, in gliomas Clin Cancer Res 13 2007 3868 3874
136. M. Kogiku, I. Ohsawa, and K. Matsumoto Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor J Clin Neurosci 15 2008 1198 1203
137. D.S. Kong, S.Y. Song, and D.H. Kim Prognostic significance of c-Met expression in glioblastomas Cancer 115 2009 140 148
138. P. Korkolopoulou, G. Levidou, and A.A. Saetta Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival Hum Pathol 39 2008 1143 1152
139. P. Korkolopoulou, E. Patsouris, and A.E. Konstantinidou Mitosin and DNA topoisomerase IIalpha: two novel proliferation markers in the prognostication of diffuse astrocytoma patient survival Appl Immunohistochem Mol Morphol 9 2001 207 214
140. P. Korkolopoulou, E. Patsouris, and A.E. Konstantinidou Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis Neuropathol Appl Neurobiol 30 2004 267 278
141. P. Korkolopoulou, M. Perdiki, and I. Thymara Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX Hum Pathol 38 2007 629 638
142. A. Korshunov, A. Golanov, and R. Sycheva Immunohistochemical markers for prognosis of cerebral glioblastomas J Neurooncol 58 2002 217 236
143. A. Korshunov, A. Golanov, and R. Sycheva Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases J Clin Pathol 52 1999 574 580
144. A. Korshunov, R. Sycheva, and A. Golanov The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years Cancer 104 2005 825 832
145. A. Korshunov, R. Sycheva, and A. Golanov Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH) Acta Neuropathol 111 2006 465 474
146. J.A. Kraus, N. Glesmann, and M. Beck Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme J Neurooncol 48 2000 89 94
147. J.A. Kraus, K. Lamszus, and N. Glesmann Molecular genetic alterations in glioblastomas with oligodendroglial component Acta Neuropathol 101 2001 311 320
148. J.A. Kraus, M. Wenghoefer, and N. Glesmann TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme J Neurooncol 52 2001 263 272
149. C.T. Kuan, K. Wakiya, and J.M. Dowell Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme Clin Cancer Res 12 2006 1970 1982
150. J.M.A. Kuijlen, J.J.A. Mooij, and I. Platteel TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme J Neurooncol 78 2006 161 171
151. H. Kuriyama, K.R. Lamborn, and J.R. O'Fallon Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas Neuro Oncol 4 2002 179 186
152. M. Labuhn, G. Jones, and E.J. Speel Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas Oncogene 20 2001 1103 1109
153. M. Labussiere, A. Idbaih, and X.W. Wang All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 Neurology 74 2010 1886 1890
154. D.R. Laks, M. Masterman-Smith, and K. Visnyei Neurosphere formation is an independent predictor of clinical outcome in malignant glioma Stem Cells 27 2009 980 987
155. L. Lalier, P.F. Cartron, and F. Pedelaborde Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme Oncogene 26 2007 4999 5009
156. G. Lama, A. Mangiola, and C. Anile Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue Int J Oncol 30 2007 1333 1342
157. K.R. Lamborn, M.D. Prados, and S.B. Kaplan Final report on the University of California-San Francisco experience with bromodeoxyuridine labeling index as a prognostic factor for the survival of glioma patients Cancer 85 1999 925 935
158. L.J. Layfield, C. Willmore, and S. Tripp Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors Appl Immunohistochem Mol Morphol 14 2006 91 96
159. A. Leins, P. Riva, and R. Lindstedt Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma Cancer 98 2003 2430 2439
160. A. Li, J. Walling, and S. Ahn Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes Cancer Res 69 2009 2091 2099
161. S. Li, T. Jiang, and G. Li Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results Neurol Res 30 2008 567 570
162. S.W. Li, X.G. Qiu, and B.S. Chen Prognostic factors influencing clinical outcomes of glioblastoma multiforme Chin Med J (Engl) 122 2009 1245 1249
163. Y. Liang, A.W. Bollen, and K.D. Aldape Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma BMC Cancer 6 2006 97
164. Y. Liang, M. Diehn, and N. Watson Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme Proc Natl Acad Sci U S A 102 2005 5814 5819
165. H. Lin, M.L. Bondy, and L.A. Langford Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance Clin Cancer Res 4 1998 2447 2454
166. M. Linnebank, A. Semmler, and S. Moskau The methylenetetrahydrofolate reductase (MTHFR) variant c.677C>T (A222V) influences overall survival of patients with glioblastoma multiforme Neuro Oncol 10 2008 548 552
167. C. Liu, G. Tian, and Y. Tu Expression pattern and clinical prognostic relevance of bone morphogenetic protein-2 in human gliomas Jpn J Clin Oncol 39 2009 625 631
168. F. Liu, P.J. Park, and W. Lai A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma Cancer Res 66 2006 10815 10823
169. L. Liu, L.M. Backlund, and B.R. Nilsson Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas J Mol Med 83 2005 917 926
170. M. Liu, B. Dai, and S.H. Kang FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells Cancer Res 66 2006 3593 3602
171. S. Liu, Z. Tian, and F. Yin Expression and functional roles of Smad1 and BMPR-IB in glioma development Cancer Invest 27 2009 734 740
172. Y. Liu, S. Shete, and C.J. Etzel Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival J Clin Oncol 28 2010 2467 2474
173. J.Y. Ljubimova, M. Fugita, and N.M. Khazenzon Association between laminin-8 and glial tumor grade, recurrence, and patient survival Cancer 101 2004 604 612
174. C. Lopez-Gines, M. Cerda-Nicolas, and R. Gil-Benso Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme Clin Neuropathol 24 2005 209 218
175. R. Lymbouridou, G. Soufla, and A.M. Chatzinikola Down-regulation of K-ras and H-ras in human brain gliomas Eur J Cancer 45 2009 1294 1303
176. A. Mangiola, G. Lama, and C. Giannitelli Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications Clin Cancer Res 13 2007 6970 6977
177. R. Martinez, J.I. Martin-Subero, and V. Rohde A microarray-based DNA methylation study of glioblastoma multiforme Epigenetics 4 2009 255 264
178. R. Martinez, V. Rohde, and G. Schackert Different molecular patterns in glioblastoma multiforme subtypes upon recurrence J Neurooncol 96 2009 321 329
179. R. Martinez, G. Schackert, and M. Esteller Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme J Neurooncol 82 2007 133 139
180. M. Martini, R. Pallini, and G. Luongo Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme Int J Cancer 123 2008 2955 2960
181. K. Matusan-Ilijas, S. Behrem, and N. Jonjic Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma Pathol Oncol Res 14 2008 293 298
182. C.A. Maurage, E. Adam, and J.F. Mineo Endocan expression and localization in human glioblastomas J Neuropathol Exp Neurol 68 2009 633 641
183. C. Mawrin, S. Diete, and T. Treuheit Prognostic relevance of MAPK expression in glioblastoma multiforme Int J Oncol 23 2003 641 648
184. K.L. McDonald, M.G. O'Sullivan, and J.F. Parkinson IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients J Neuropathol Exp Neurol 66 2007 405 417
185. P.E. McKeever, L. Junck, and M.S. Strawderman Proliferation index is related to patient age in glioblastoma Neurology 56 2001 1216 1218
186. M. Mellai, V. Caldera, and L. Annovazzi MGMT promoter hypermethylation in a series of 104 glioblastomas Cancer Genomics Proteomics 6 2009 219 227
187. Y. Meng, M. Kujas, and Y. Marie Expression of TLR9 within human glioblastoma J Neurooncol 88 2008 19 25
188. P. Metellus, B. Coulibaly, and I. Nanni Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort Cancer 115 2009 4783 4794
189. J.F. Mineo, A. Bordron, and M. Baroncini Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma J Neurooncol 85 2007 281 287
190. M. Mittelbronn, D. Capper, and B. Bunz De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival Neuropathol Appl Neurobiol 33 2007 299 307
191. Y. Miyajima, Y. Sato, and H. Oka Prognostic significance of nuclear DJ-1 expression in astrocytoma Anticancer Res 30 2010 265 269
192. L. Montanini, C. Regna-Gladin, and M. Eoli Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas J Neurooncol 74 2005 87 89
193. S.I. Moskowitz, T. Jin, and R.A. Prayson Role of MIB1 in predicting survival in patients with glioblastomas J Neurooncol 76 2006 193 200
194. A. Murat, E. Migliavacca, and T. Gorlia Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma J Clin Oncol 26 2008 3015 3024
195. M. Nagane, K. Kobayashi, and A. Ohnishi Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide Jpn J Clin Oncol 37 2007 897 906
196. T. Nakagawa, K. Ido, and T. Sakuma Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas Neuropathology 29 2009 379 388
197. M. Nakamura, E. Ishida, and K. Shimada Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas Lab Invest 85 2005 165 175
198. M. Nakamura, N. Konishi, and Y. Hiasa Frequent alterations of cell-cycle regulators in astrocytic tumors as detected by molecular genetic and immunohistochemical analyses Brain Tumor Pathol 15 1998 83 88
199. I. Nakano, M. Masterman-Smith, and K. Saigusa Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells J Neurosci Res 86 2008 48 60
200. K. Nakatani, N. Yoshimi, and H. Mori The significance of the expression of tumor suppressor gene DCC in human gliomas J Neurooncol 40 1998 237 242
201. N. Nathoo, R.A. Prayson, and J. Bondar Increased expression of 5-lipoxygenase in high-grade astrocytomas Neurosurgery 58 2006 347 354 [discussion-54]
202. E.W. Newcomb, H. Cohen, and S.R. Lee Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes Brain Pathol 8 1998 655 667
203. J.A.R. Nicoll, E. Zunarelli, and R. Rampling Involvement of apolipoprotein E in glioblastoma: immunohistochemistry and clinical outcome Neuroreport 14 2003 1923 1926
204. J.M. Nigro, A. Misra, and L. Zhang Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma Cancer Res 65 2005 1678 1686
205. S. Nobusawa, T. Watanabe, and P. Kleihues IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas Clin Cancer Res 15 2009 6002 6007
206. J.L. Oblinger, D.K. Pearl, and C.L. Boardman Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients Neuropathol Appl Neurobiol 32 2006 410 418
207. R.D. Oehring, M. Miletic, and M.M. Valter Vascular endothelial growth factor (VEGF) in astrocytic gliomas-a prognostic factor? J Neurooncol 45 1999 117 125
208. H. Ohgaki, P. Dessen, and B. Jourde Genetic pathways to glioblastoma: a population-based study Cancer Res 64 2004 6892 6899
209. H. Ohgaki, and P. Kleihues Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas J Neuropathol Exp Neurol 64 2005 479 489
210. R. Pallini, L. Ricci-Vitiani, and G.L. Banna Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme Clin Cancer Res 14 2008 8205 8212
211. S. Park, K.J. Hatanpaa, and Y. Xie The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma Cancer Res 69 2009 2809 2816
212. C.E. Pelloski, K.V. Ballman, and A.F. Furth Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma J Clin Oncol 25 2007 2288 2294
213. C.E. Pelloski, E. Lin, and L. Zhang Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma Clin Cancer Res 12 2006 3935 3941
214. M. Perdiki, P. Korkolopoulou, and I. Thymara Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival Mol Cell Biochem 295 2007 75 83
215. C. Piperi, M.S. Themistocleous, and G.A. Papavassiliou High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome Mol Med 16 2009 1 9
216. W.B. Pope, J.H. Chen, and J. Dong Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis Radiology 249 2008 268 277
217. M. Preusser, E. Gelpi, and R. Matej No prognostic impact of survivin expression in glioblastoma Acta Neuropathol 109 2005 534 538
218. M. Preusser, H. Heinzl, and E. Gelpi Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group Cancer 107 2006 162 170
219. M. Preusser, T. Strobel, and P. Birner Presence of D110 antigen expressing immunocompetent cells in glioblastoma associates with prolonged survival Neuropathol Appl Neurobiol 30 2004 608 614
220. V.K. Puduvalli, A.P. Kyritsis, and K.R. Hess Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival Int J Oncol 17 2000 963 969
221. A.L. Quan, G.H. Barnett, and S.Y. Lee Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme Int J Radiat Oncol Biol Phys 63 2005 695 703
222. J. Rahnenfuhrer, N. Beerenwinkel, and W.A. Schulz Estimating cancer survival and clinical outcome based on genetic tumor progression scores Bioinformatics 21 2005 2438 2446
223. S.M. Ranuncolo, M. Varela, and A. Morandi Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas J Neurooncol 68 2004 113 121
224. S.M. Raza, G.N. Fuller, and C.H. Rhee Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis Clin Cancer Res 10 2004 212 221
225. J.F. Reavey-Cantwell, R.I. Haroun, and M. Zahurak The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature J Neurooncol 55 2001 195 204
226. P.S. Reddy, S. Umesh, and B. Thota PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value Cancer Biol Ther 7 2008 663 668
227. S.P. Reddy, R. Britto, and K. Vinnakota Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis Clin Cancer Res 14 2008 2978 2987
228. F. Ria, M. Landriscina, and F. Remiddi The level of manganese superoxide dismutase content is an independent prognostic factor for glioblastoma. Biological mechanisms and clinical implications Br J Cancer 84 2001 529 534
229. Mde.C. Ribeiro, L.M. Coutinho, and A. Hilbig The role of apoptosis, cell proliferation index, bcl-2, and p53 in glioblastoma prognosis Arq Neuropsiquiatr 62 2004 262 270
230. J.N. Rich, C. Hans, and B. Jones Gene expression profiling and genetic markers in glioblastoma survival Cancer Res 65 2005 4051 4058
231. A.L. Rivera, C.E. Pelloski, and M.R. Gilbert MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma Neuro Oncol 12 2009 116 121
232. M. Rodero, Y. Marie, and M. Coudert Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma J Clin Oncol 26 2008 5957 5964
233. F.J. Rodriguez, S.N. Thibodeau, and R.B. Jenkins MGMT immunohistochemical expression and promoter methylation in human glioblastoma Appl Immunohistochem Mol Morphol 16 2008 59 65
234. A.A. Roma, and R.A. Prayson Fascin expression in 90 patients with glioblastoma multiforme Ann Diagn Pathol 9 2005 307 311
235. Y. Ruano, M. Mollejo, and F.I. Camacho Identification of survival-related genes of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma multiforme Cancer 112 2008 1575 1584
236. Y. Ruano, T. Ribalta, and A.R. de Lope Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration Am J Clin Pathol 131 2009 257 263
237. J. Sadones, A. Michotte, and P. Veld MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma Eur J Cancer 45 2009 146 153
238. A. Saidi, S. Javerzat, and A. Bellahcene Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma Int J Cancer 122 2008 2187 2198
239. K. Saigusa, N. Hashimoto, and H. Tsuda Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas Cancer Sci 96 2005 676 683
240. S. Saikali, T. Avril, and B. Collet Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy J Neurooncol 81 2007 139 148
241. T. Saito, S. Hama, and Y. Kajiwara Prognosis of cerebellar glioblastomas: correlation between prognosis and immunoreactivity for epidermal growth factor receptor compared with supratentorial glioblastomas Anticancer Res 26 2006 1351 1357
242. A. Salmaggi, M. Eoli, and S. Frigerio Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma J Neurooncol 62 2003 297 303
243. V. Samaras, A. Stamatelli, and E. Samaras Comparative immunohistochemical analysis of aurora-A and aurora-B expression in human glioblastomas. Associations with proliferative activity and clinicopathological features Pathol Res Pract 205 2009 765 773
244. M. Sano, N. Genkai, and N. Yajima Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients Oncol Rep 16 2006 1093 1098
245. M.E. Scheurer, E. Amirian, and Y. Cao Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma Clin Cancer Res 14 2008 6640 6646
246. M. Schiebe, P. Ohneseit, and W. Hoffmann Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors J Neurooncol 49 2000 197 203
247. M. Schiebe, P. Ohneseit, and W. Hoffmann Loss of heterozygosity at 11p15 and p53 alterations in malignant gliomas J Cancer Res Clin Oncol 127 2001 325 328
248. J. Schittenhelm, K. Trautmann, and G. Tabatabai Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival Mod Pathol 22 2009 1600 1611
249. M.C. Schmidt, S. Antweiler, and N. Urban Impact of genotype and morphology on the prognosis of glioblastoma J Neuropathol Exp Neurol 61 2002 321 328
250. C.A. Scrideli, C.G. Carlotti Jr., and J.F. Mata Prognostic significance of co-overexpression of the EGFR/IGFBP-2/HIF-2A genes in astrocytomas J Neurooncol 83 2007 233 239
251. Z. Sheng, L. Li, and L.J. Zhu A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications Nat Med 16 2010 671 677
252. H.A. Shih, R.A. Betensky, and M.V. Dorfman Genetic analyses for predictors of radiation response in glioblastoma Int J Radiat Oncol Biol Phys 63 2005 704 710
253. N. Shinojima, K. Tada, and S. Shiraishi Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme Cancer Res 63 2003 6962 6970
254. M. Shirahata, S. Oba, and K. Iwao-Koizumi Using gene expression profiling to identify a prognostic molecular spectrum in gliomas Cancer Sci 100 2009 165 172
255. S. Shiraishi, K. Tada, and H. Nakamura Influence of p53 mutations on prognosis of patients with glioblastoma Cancer 95 2002 249 257
256. T. Shono, P.J. Tofilon, and J.M. Bruner Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations Cancer Res 61 2001 4375 4381
257. P. Shrestha, T. Saito, and S. Hama Geminin: a good prognostic factor in high-grade astrocytic brain tumors Cancer 109 2007 949 956
258. M. Sie, M. Wagemakers, and G. Molema The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme J Neurosurg 110 2009 147 155
259. A.J. Sigurdson, M.L. Bondy, and K.R. Hess Gamma-ray mutagen sensitivity and survival in patients with glioma Clin Cancer Res 4 1998 3031 3035
260. M.L. Simmons, K.R. Lamborn, and M. Takahashi Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients Cancer Res 61 2001 1122 1128
261. M. Simon, M. Ludwig, and R. Fimmers Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme Neurosurgery 59 2006 1078 1085 [discussion 85]
262. P. Sminia, T.R. Stoter, and P. van der Valk Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme J Cancer Res Clin Oncol 131 2005 653 661
263. J.S. Smith, A. Perry, and T.J. Borell Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas J Clin Oncol 18 2000 636 645
264. J.S. Smith, I. Tachibana, and S.M. Passe PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme J Natl Cancer Inst 93 2001 1246 1256
265. A. Soling, M. Sackewitz, and M. Volkmar Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma Clin Cancer Res 11 2005 249 258
266. Y. Sonoda, T. Kumabe, and M. Watanabe Long-term survivors of glioblastoma: clinical features and molecular analysis Acta Neurochir (Wien) 151 2009 1349 1358
267. S. Spiegl-Kreinecker, C. Pirker, and M. Filipits O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients Neuro Oncol 12 2009 28 36
268. A.M. Stark, H.H. Hugo, and P. Witzel Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme Zentralbl Neurochir 64 2003 30 36
269. A.R. Stone, W. Bobo, and D.J. Brat Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma Am J Pathol 165 2004 1151 1161
270. R.J. Strege, C. Godt, and A.M. Stark Protein expression of Fas, Fas ligand, Bcl-2 and TGFbeta2 and correlation with survival in initial and recurrent human gliomas J Neurooncol 67 2004 29 39
271. T. Strojnik, J. Kos, and B. Zidanik Immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors Clin Cancer Res 5 1999 559 567
272. K. Tada, S. Shiraishi, and T. Kamiryo Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival J Neurosurg 95 2001 651 659
273. M. Tada, R. Matsumoto, and R.D. Iggo Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations Cancer Res 58 1998 1793 1797
274. J. Tang, W. Shao, and M.T. Dorak Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme Cancer Epidemiol Biomarkers Prev 14 2005 2040 2044
275. Y. Tanizaki, Y. Sato, and H. Oka Expression of autocrine motility factor mRNA is a poor prognostic factor in high-grade astrocytoma Pathol Int 56 2006 510 515
276. A. Tchirkov, T. Khalil, and E. Chautard Interleukin-6 gene amplification and shortened survival in glioblastoma patients Br J Cancer 96 2007 474 476
277. A. Tchirkov, C. Rolhion, and J.L. Kemeny Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas Br J Cancer 88 2003 516 520
278. S.H. Torp, S. Gulati, and E. Johannessen Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study J Exp Clin Cancer Res 26 2007 353 359
279. Y. Tu, J. Lu, and J. Fu Over-expression of neuroepithelial-transforming protein 1 confers poor prognosis of patients with gliomas Jpn J Clin Oncol 40 2010 388 394
280. O. Tynninen, O. Carpen, and J. Jaaskelainen Ezrin expression in tissue microarray of primary and recurrent gliomas Neuropathol Appl Neurobiol 30 2004 472 477
281. R. Ueda, K. Yoshida, and T. Kawase Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients Int J Cancer 120 2007 1704 1711
282. S. Umesh, A. Tandon, and V. Santosh Clinical and immunohistochemical prognostic factors in adult glioblastoma patients Clin Neuropathol 28 2009 362 372
283. J.R. Van Brocklyn, C.A. Jackson, and D.K. Pearl Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines J Neuropathol Exp Neurol 64 2005 695 705
284. J. Vaquero, M. Zurita, and S. Coca Imbalance between apostain expression and proliferative index can predict survival in primary glioblastoma Acta Neurochir (Wien) 144 2002 151 155 [discussion 155-6]
285. J. Vaquero, M. Zurita, and C. Morales Prognostic significance of endothelial surface score and MIB-1 labeling index in glioblastoma J Neurooncol 46 2000 11 16
286. E. Vauleon, N. Auger, and A. Benouaich-Amiel The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma Cancer Genet Cytogenet 172 2007 33 37
287. R.G. Verhaak, K.A. Hoadley, and E. Purdom Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
288. L. Wang, Q. Wei, and L.E. Wang Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation J Clin Oncol 24 2006 1627 1632
289. L.F. Wang, E. Fokas, and M. Bieker Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients Oncol Rep 19 2008 151 156
290. A. Warth, P. Simon, and D. Capper Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival J Neurosci Res 85 2007 1336 1346
291. T. Watanabe, Y. Katayama, and C. Komine O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course Int J Cancer 113 2005 581 587
292. K.C. Wei, C.Y. Huang, and P.Y. Chen Evaluation of the prognostic value of CD44 in glioblastoma multiforme Anticancer Res 30 2010 253 259
293. J.W. Welsh, R.K. Ellsworth, and R. Kumar Rad51 protein expression and survival in patients with glioblastoma multiforme Int J Radiat Oncol Biol Phys 74 2009 1251 1255
294. S. Wemmert, M. Bettscheider, and S. Alt P15 promoter methylation - a novel prognostic marker in glioblastoma patients Int J Oncol 34 2009 1743 1748
295. S. Wemmert, R. Ketter, and J. Rahnenfuhrer Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment Neoplasia 7 2005 883 893
296. R.N. Wiltshire, J.E. Herndon 2nd, and A. Lloyd Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications J Mol Diagn 6 2004 166 179
297. M. Wrensch, J.K. Wiencke, and J. Wiemels Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival Cancer Res 66 2006 4531 4541
298. D. Xie, D. Yin, and H.J. Wang Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas Clin Cancer Res 10 2004 2072 2081
299. Q. Xu, X. Yuan, and G. Liu Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas Stem Cells 26 2008 3018 3026
300. K. Yachi, T. Watanabe, and T. Ohta Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas Int J Oncol 33 2008 469 475
301. A.K. Yadav, J.J. Renfrow, and D.M. Scholtens Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas Jama 302 2009 276 289
302. S.M. Yamada, S. Yamada, and Y. Hayashi Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas Neurol Res 24 2002 244 248
303. Y. Yao, T. Kubota, and H. Takeuchi Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody Neuropathology 25 2005 201 206
304. D. Yin, S. Ogawa, and N. Kawamata High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray Mol Cancer Res 7 2009 665 677
305. Y. Yoshida, M. Nakada, and N. Sugimoto Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival Int J Cancer 126 2010 2341 2352
306. I. Zawlik, D. Kita, and S. Vaccarella Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas Brain Pathol 19 2009 188 194
307. I. Zawlik, S. Vaccarella, and D. Kita Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study Neuroepidemiology 32 2009 21 29
308. J. Zhang, B. Liu, and X. Jiang A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors PLoS One 4 2009 e6274
309. H. Ohgaki, and P. Kleihues Genetic alterations and signaling pathways in the evolution of gliomas Cancer Science 100 2009 2235 2241
310. M.J. Fine, M.A. Smith, and C.A. Carson Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis Jama 275 1996 134 141
311. L.A. Mandell, R.G. Wunderink, and A. Anzueto Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis 44 2007 S27 S72
312. OCEBM Levels of Evidence Working Group The Oxford 2011 Levels of Evidence 2011 Oxford Centre for Evidence-Based Medicine http://www.cebm.net/index.aspx?o=5653